Physiology and pathophysiology of the adipose tissue renin-angiotensin system

Hypertension

Volumn 35, Issue 6, 2000, Pages 1270-1277

  Engeli, Stefan ^c   Negrel, Raymond ^a   Sharma, Arya M ^b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NONE

Author keywords

Adipose tissue; Angiotensin II; Hypertension, obesity; Obesity; Prostacyclin; Renin angiotensin system

Indexed keywords

ADIPOSE TISSUE; ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0034095811     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.6.1270     Document Type: Article

References (123)

1. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept. 1993;43:1-20.
2. Unger T, Gohlke P. Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors. Am Heart J. 1990;65:3I-10I.
3. Dzau VJ. Circulating versus local RAS in cardiovascular homeostasis. Circulation. 1988;77(suppl I):I-4-I-13.
4. Lee MA, Bohm M, Paul M, Ganten D. Tissue renin-angiotensin systems: their role in cardiovascular disease. Circulation. 1993;87(suppl IV):IV-7-IV-13.
5. Ganong WF. Origin of the Ang II secreted by cells. Proc Soc Exp Biol Med. 1994;205:213-219.
6. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993;87:1816-1828.
7. Studer R, Reinecke H, Muller B, Holtz J, Just H, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart: quantification by competitive RNA polymerase chain reaction. J Clin Invest. 1994;94:301-310.
8. Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart: mediation by the AT1 receptor. Am J Hypertens. 1992;5:276-280.
9. Mazzolai L, Nussberger J, Aubert JF, Brunner DB, Gabbiani G, Brunner HR, Pedrazzini T. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension. 1998;31:1324-1330.
10. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming system in humans. Am J Hypertens. 1996;9:277-284.
11. Lai KN, Leung JCK, Lai KB, To WY, Yeung VTF, Lai FMM. Gene expression of the renin-angiotensin system in human kidney. J Hypertens. 1998;16:91-102.
12. Braam B, Koomans HA. Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens. 1996;5:89-96.
13. Rosenberg ME, Smith LJ, Correa Rotter R, Hostetter TH. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int. 1994;45:403-410.
14. Mizuiri S, Yoshikawa H, Tanegashima M, Miyagi M, Kobayashi M, Sakai K, Hayashi I, Aikawa A, Ohara T, Hasegawa A. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis. 1998;31:301-307.
15. Dahlöf B, Devereux R, De Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The Losartan Intervention for Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. Am J Hypertens. 1997;10:705-713.
16. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial (SAVE Investigators). N Engl J Med. 1992;327-669-677.
17. Maisch B. Ventricular remodeling. Cardiology. 1996;87(suppl 1):2-10.
18. Latini R, Maggioni AP, Zuanetti G. Myocardial infarction: when and how should we initiate treatment with ACE inhibitors. Cardiology. 1996;87(suppl 1):16-22.
19. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet. 1997;349:747-752.
20. Campbell DJ, Habener JF. Cellular localization of AGT gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology. 1987;121:1616-1626.
21. Cassis LA, Saye J, Peach MJ. Location and regulation of rat angiotensinogen messenger RNA. Hypertension. 1988;11:591-596.
22. Cassis LA, Lynch KR, Peach MJ. Localization of angiotensinogen messenger RNA in rat aorta. Circ Res. 1988;62:1259-1262.
23. Naftilan AJ, Zuo WM, Inglefinger J, Ryan TJ Jr, Pratt RE, Dzau VJ. Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest. 1991;87:1300-1311.
24. Jones BH, Standridge MK, Taylor JW, Moustaïd N. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Physiol. 1997;273:R236-R242.
25. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens. 1999;17:555-560.
26. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab. 1998;83:3925-3929.
27. Schling P, Mallow H, Trindl A, Loffler G. Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord. 1999;23:336-341.
28. Saye J, Lynch KR, Peach MJ. Changes in angiotensinogen messenger RNA in differentiating 3T3-F442A adipocytes. Hypertension. 1990;15: 867-871.
29. Saye JA, Cassis LA, Sturgill TW, Lynch KR, Peach MJ. Angiotensinogen gene expression in 3T3-L1 cells. Am J Physiol. 1989;256: C448-C451.
30. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev. 1998;78:783-809.
31. Safonova I, Aubert J, Negrel R, Ailhaud G. Regulation by fatty acids of angiotensinogen gene expression in preadipose cells. Biochem J. 1997; 322:235-239.
32. Aubert J, Darimont C, Safonova I, Ailhaud G, Negrel R. Regulation by glucocorticoids of AGT gene expression and secretion in adipose cells. Biochem J. 1997;328:701-706.
33. Tamura K, Umemura S, Iwamoto T, Yamaguchi S, Kobayashi S, Takeda K, Tokita Y, Takagi N, Murakami K, Fukamizu A, Ishii M. Molecular mechanism of adipogenic activation of the angiotensinogen gene. Hypertension. 1994;23:364-368.
34. Tamura K, Tanimoto K, Ishii M, Murakami K, Fukamizu A. Proximal and core DNA elements are required for efficient angiotensinogen promoter activation during adipogenic differentiation. J Biol Chem. 1993;268:15024-15032.
35. McGehee REJ, Ron D, Brasier AR, Habener JF. Differentiation-specific element: a cis-acting developmental switch required for the sustained transcriptional expression of the AGT gene during hormonal-induced differentiation of 3T3-L1 fibroblasts to adipocytes. Mol Endocrinol. 1993;7:551-560.
36. McGehee RE Jr, Habener JF. Differentiation-specific element binding protein (DSEB) binds to a defined element in the promoter of the AGT gene required for the irreversible induction of gene expression during differentiation of 3T3-L1 adipoblasts to adipocytes. Mol Endocrinol. 1995;9:487-501.
37. Aubert J, Safonova I, Negrel R, Ailhaud G. Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells. Biochem Biophys Res Commun. 1998;250:77-82.
38. Cassis LA. Downregulation of the renin-angiotensin system in streptozotocin-diabetic rats. Am J Physiol. 1992;262:E105-E109.
39. Turban S, Hainault I, André J, Quignard-Boulangé A, Guerre-Millo M. Differential regulation of leptin and AGT secretion in rat adipose cells. Eating Weight Disord. 1999;4:34. Abstract.
40. Ardévol A, Rayner DV, Duncan JS, Trayhurn P. Sympathetic blockade with α-MPT counteracts the inhibitory effects of fasting on leptin production. Int J Obes Relat Metab Disord. 1999;23(suppl 5):S23. Abstract.
41. Harp JB, DiGirolamo M. Components of the renin-angiotensin system in adipose tissue: changes with maturation and adipose mass enlargement. J Gerontol A Biol Sci Med Sci. 1995;50:B270-B276.
42. Hainault I, Nebout G, Ardouin B, Quignard-Boulangé A. Developmental changes in AGT expression and its secretion in the Zucker rat: adipose tissue-specific effect of FA genotype. Int J Obes Relat Metab Disord. 1998;22(suppl 3):S103. Abstract.
43. Crandall DL, Herzlinger HE, Saunders BD, Kral JG. Developmental aspects of the adipose tissue renin-angiotensin system: therapeutic implications. Drug Dev Res. 1994;32:117-125.
44. Sérazin-Leroy V, Morot M, De Mazancourt P, Giudicelli Y. In vivo AGT gene expression in rat adipocytes: regional specificities and regulation by androgens. Int J Obes Relat Metab Disord. 1998;22(suppl 3):S102. Abstract.
45. Giacchetti G, Faloia E, Sardu C, Mariniello B, Garrapa GGM, Gatti C, Camilloni MA, Mantero F. Different gene expression of the RAS in human subcutaneous and visceral adipose tissue. Int J Obes Relat Metab Disord. 1999;23(suppl 5):S71. Abstract.
46. Van Harmelen V, Reynisdottir S, Bergstedt-Lindqvist S, Elizalde M, Lundkvist I, Arner P. Comparison of AGT mRNA levels in fat tissue from obese, non-obese, hypertensive and normotensive subjects. Int J Obes Relat Metab Disord. 1999;23(suppl 5):S24. Abstract.
47. Shenoy U, Cassis L. Characterization of renin activity in brown adipose tissue. Am J Physiol. 1997;272:C989-C999.
48. Saye JA, Ragsdale NV, Carey RM, Peach MJ. Localization of angiotensin peptide-forming enzymes of 3T3-F442A adipocytes. Am J Physiol. 1993;264:C1570-C1576.
49. Danser AH, van Kats JP, Admiraal PJ, Derkx FH, Lamers JM, Verdouw PD, Saxena PR, Schalekamp MA. Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis. Hypertension. 1994;24: 37-48.
50. Danser AH, Schalekamp MA. Is there an internal cardiac renin-angiotensin system? Heart. 1996;76:28-32.
51. De Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MADH. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart: local production of angiotensin. Hypertension. 1997;29:1240-1251.
52. Inoue H, Takahashi S, Miyake Y. Modulation of active renin secretion by renin-binding protein (RnBP) in mouse pituitary AtT-20 cells transfected with human renin and RnBP cDNAs. J Biochem. 1992;111: 407-412.
53. Maru I, Ohta Y, Murata K, Tsukada Y. Molecular cloning and identification of N-acyl-D-glucosamine 2-epimerase from porcine kidney as a renin-binding protein. J Biol Chem. 1996;271:16294-16299.
54. Knoll A, Schunkert H, Reichwald K, Danser AH, Bauer D, Platzer M, Stein G, Rosenthal A. Human renin binding protein: complete genomic sequence and association of an intronic T/C polymorphism with the prorenin level in males. Hum Mol Genet. 1997;6:1527-1534.
55. Jonsson JR, Game PA, Head RJ, Frewin DB. The expression and localisation of ACE mRNA in human adipose tissue. Blood Press 1994;3:72-75.
56. Crandall DL, Herzlinger HE, Saunders BD, Zolotor RC, Feliciano L, Cervoni P. Identification and characterization of Ang II receptors in rat adipocyte membranes. Metabolism. 1993;42:511-515.
57. Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Krai JG. Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res. 1994;35:1378-1385.
58. Crandall DL, Armellino DC, Busler DE, McHendry-Rinde B, Kral JG. Ang II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology. 1999;140:154-158.
59. Burson JM, Aguilera G, Gross KW, Sigmund CD. Differential expression of angiotensin receptor 1A and 1B in mouse. Am J Physiol. 1994;267:E260-E267.
60. Schling P, Löffler, G. Angiotensin II receptors during differentiation of human preadipocytes. Int J Obes Relat Metab Disord. 1998;22(suppl 3):S99. Abstract.
61. Darimont C, Vassaux G, Ailhaud G, Negrel R. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology. 1994;135:2030-2036.
62. Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology. 1997;138: 1512-1519.
63. Cassis LA, Fettinger MJ, Roe AL, Shenoy UR, Howard G. Characterization and regulation of Ang II receptors in rat adipose tissue: Ang receptors in adipose tissue. Adv Exp Med Biol. 1996;396:39-47.
64. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension. 1996; 27:760-765.
65. Kranzhöfer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun. 1999;257: 826-828.
66. Sil P, Sen S. Ang II and myocyte growth. Hypertension. 1997;30: 209-216.
67. Moriyama T, Kawada N, Akagi Y, Ando A, Horio M, Yamauchi A, Nagata K, Imai E, Hori M. TCV-116 inhibits interstitial fibrosis and HSP47 mRNA in rat obstructive nephropathy. Kidney Int Suppl. 1997; 63:5232-235.
68. Chung O, Stoll M, Unger T. Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Blood Press Suppl. 1996;2:47-52.
69. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA. 1995;92:10663-10667.
70. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol. 1996;122:59-67.
71. Lyle RE, Habener JF, McGehee RE Jr. Antisense oligonucleotides to differentiation-specific element binding protein (DSEB) mRNA inhibit adipocyte differentiation. Biochem Biophys Res Commun. 1996;228: 709-715.
72. Negrel R, Ailhaud G. Metabolism of arachidonic acid and prostaglandin synthesis in the preadipocyte clonal line Ob 1771. Biochem Biophys Res Commun. 1981;68:768-777.
73. Hyman BT, Stoll LL, Spector AA. Prostaglandin production by 3T3-L1 cells in culture. Biochim Biophys Acta. 1982;713:375-385.
74. Richelsen B. Prostaglandins in adipose tissue. Dan Med Bull. 1991;38: 228-244.
75. Gaillard D, Negrel R, Lagarde M, Ailhaud G. Requirement and role of arachidonic acid in the differentiation of preadipose cells. Biochem J. 1989;257:389-397.
76. Negrel R, Gaillard D, Ailhaud G. Prostacyclin as a potent effector of adipose cell differentiation. Biochem J. 1989;257:399-405.
77. Vassaux G, Gaillard D, Ailhaud G, Negrel R. Prostacyclin is a specific effector of adipose cell differentiation: its dual role as a cAMP- and calcium-elevating agent. J Biol Chem. 1992;267:11092-11097.
78. Catalioto RM, Gaillard D, Maclouf J, Ailhaud G. Negrel R. Autocrine control of adipose cell differentiation by prostacyclin and PGF2a. Biochim Biophys Acta. 1991;1091:364-369.
79. Negrel R. Prostacyclin as a critical prostanoid in adipogenesis. Prostaglandins Leukot Essent Fatty Acids. 1999;60:383-386.
80. Axelrod L, Minnich AK, Ryan CA. Stimulation of prostacyclin production in isolated rat adipocytes by ang II, vasopressin, and bradykinin: evidence for 2 separate mechanisms of prostaglandin synthesis. Endocrinology. 1985;116:2548-2553.
81. Darimont C, Vassaux G, Gaillard D, Ailhaud G, Negrel R. In situ microdialysis of prostaglandins in adipose tissue: stimulation of prostacyclin release by angiotensin II. Int J Obes Relat Metab Disord. 1994; 18:783-788.
82. Mallow H, Trindl A, Löffler G. Production of angiotensin II receptors type 1 (AT1) and type 2 (AT2) during the differentiation of 3T3-L1 preadipocytes in culture. Eating Weight Disord. 1999;4:41. Abstract.
83. Zorad S, Fickova M, Zelezna B, Macho L, Krai JG. The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Gen Physiol Biophys. 1995;14:383-391.
84. Brink M, Wellen J, Delafontaine P. Ang II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest. 1996;97:2509-2516.
85. Harrison-Bernard LM, El-Dahr SS, O'Leary DF, Navar LG. Regulation of angiotensin II type 1 receptor mRNA and protein in angiotensin II-induced hypertension. Hypertension. 1999;33:340-346.
86. Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA. Mechanisms contributing to ang II regulation of body weight. Am J Physiol. 1998;274:E867-E876.
87. McGrath BP, Matthews PG, Louis W, Howes L, Whitworth JA, Kincaid Smith PS, Fraser I, Scheinkestel C, MacDonald G, Railings M. Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. J Cardiovasc Pharmacol. 1990;16:831-838.
88. Campbell DJ, Duncan AM, Kladis A, Harrap SB. Converting enzyme inhibition and its withdrawal in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1995;26:426-436.
89. Enalapril in Hypertension Study Group (UK). Enalapril in essential hypertension: a comparative study with propranolol Br J Clin Pharmacol. 1984;18:51-56.
90. Cassis LA. Angiotensin II in brown adipose tissue from young and adult Zucker obese and lean rats. Am J Physiol. 1994;266:E453-E458.
91. Cassis LA. Role of angiotensin II in brown adipose thermogenesis during cold acclimation. Am J Physiol. 1993;265:E860-E865.
92. Cassis L, Laughter A, Fettinger M, Akers S, Speth R, Burke G, King V, Dwoskin L. Cold exposure regulates the renin-angiotensin system. J Pharmacol Exp Ther. 1998;286:718-726.
93. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
94. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
95. Walker WG, Whelton PK, Saito H, Russell RP, Hermann J. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension. 1979;1:287-291.
96. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, Corvol P. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
97. Caulfield M, Lavender P, Newell-Price J, Kamdar S, Farrall M, Clark AJL. Angiotensinogen in human essential hypertension. Hypertension. 1996;28:1123-1125.
98. Tamura K, Umemura S, Nyui N, Yamakawa T, Yamaguchi S, Ishigami T, Tanaka S, Tanimoto K, Takagi N, Sekihara H, Murakami K, Ishii M. Tissue-specific regulation of angiotensinogen gene expression in spontaneously hypertensive rats. Hypertension. 1996;27:1216-1223.
99. Nyui N, Tamura K, Yamaguchi S, Nakamaru M, Ishigami T, Yabana M, Kihara M, Ochiai H, Miyazaki N, Umemura S, Ishii M. Tissue angiotensinogen gene expression induced by lipopolysaccharide in hypertensive rats. Hypertension. 1997;30:859-867.
100. Cooper R, McFarlane Anderson N, Bennett FI, Wilks R, Puras A, Tewksbury D, Ward R, Forrester T. ACE, AGT, and obesity, a potential pathway leading to hypertension. J Hum Hypertens. 1997;11:107-111.
101. Cooper R, Forrester T, Ogunbiyi O, Muffinda J. AGT levels and obesity in four black populations: ICSHIB Investigators. J Hypertens. 1998; 16: 571-575.
102. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest. 1995;95:948-953.
103. Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamaru M, Ishigami T, Yabana M, Kihara M, Inoue S, Ishii M. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens. 1997;10: 629-633.
104. Hegele RA, Brunt JH, Connelly PW. Genetic variation on chromosome 1 associated with variation in body fat distribution in men. Circulation. 1995;92:1089-1093.
105. Licata G, Scaglione R, Ganguzza A, Corrao S, Donatelli M, Parrinello G, Dichiara MA, Merlino G, Cecala MG. Central obesity and hypertension: relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens. 1994;7:314-320.
106. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens. 1994;7: 886-893.
107. Alonso-Galicia M, Brands MW, Zappe DH, Hall JE. Hypertension in obese Zucker rats: role of angiotensin II and adrenergic activity. Hypertension. 1996;28:1047-1054.
108. Schorr U, Blaschke K, Turan S, Distler A, Sharma AM. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens. 1998;16:1475-1480.
109. Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS, Hamilton BS, Paglia D, Kwan AY, Deitel M, Lonnqvist F, Arner P, Nordfors L, Schalling M. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med. 1995;1:950-953.
110. Hainault I, Oppert JM, Basdevant A, Coussieu C, Guy-Grand B, Quignard-Boulangé A. Evidence of AGT and TNF-α secretion by human adipocytes from obese patients. Eating Weight Disord. 1999;4:31. Abstract.
111. Frederich RCJ, Kahn BB, Peach MJ, Flier JS. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension. 1992;19: 339-344.
112. Ernsberger P, Koletsky RJ, Baskin JS, Foley M. Refeeding hypertension in obese spontaneously hypertensive rats. Hypertension. 1994;24: 699-705.
113. Ernsberger P, Koletsky RJ, Baskin JS, Collins LA. Consequences of weight cycling in obese spontaneously hypertensive rats. Am J Physiol. 1996;270:R864-R872.
114. Ernsberger P, Nelson DO. Refeeding hypertension in dietary obesity. Am J Physiol. 1988;254:R47-R55.
115. Contreras RJ, King S, Rives L, Williams A, Wattleton T. Dietary obesity and weight cycling in rats: model of stress-induced hypertension? Am J Physiol. 1991;261:R848-R857.
116. Aubert J, Ailhaud G, Negrel R. Evidence for a novel regulatory pathway activated by (carba)prostacyclin in preadipose and adipose cells. FEBS Lett. 1996;397:117-121.
117. Brun RP, Tontonoz P, Forman BM, Ellis R, Chen J, Evans RM, Spiegelman BM. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 1996;10:974-984.
118. Amri EZ, Bonino F, Ailhaud G, Abumrad NA, Grimaldi PA. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes: homology to peroxisome proliferator-activated receptors. J Biol Chem. 1994;270:2367-2371.
119. Bastié C, Holts D, Gaillard D, Jehl-Pietri C, Grimaldi PA. Expression of peroxisome proliferator-activated receptor PPARdelta promotes induction of PPARgama and adipocyte differentiation in 3T3-C2 fibroblasts. J Biol Chem. 1999;274:21920-21925.
120. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1997;94:4312-4317.
121. Tamura K, Umemura S, Yamakawa T, Nyui N, Hibi K, Watanabe Y. Ishigami T, Yabana M, Tanaka SI, Sekihara H, Murakami K, Ishii M. Modulation of tissue AGT gene expression in genetically obese hypertensive rats. Am J Physiol. 1997;272:R1704-R1711.
122. Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, Fukamizu A, Murakami K. Angiotensinogen-deficient mice with hypotension. J Biol Chem. 1994;269:31334-31337.
123. Massiéra F, Murakami K, Fukamizu A, Negrel R, Ailhaud G, Teboul M. Effects of high fat diet on adiposity in AGT deficient and wild type mice. Eating Weight Disord. 1999;4:41. Abstract.